BD offers streamlined reporting capabilities for COVID-19 data

Nov. 25, 2020

Becton, Dickinson and Company (BD) announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be generated from BD Synapsys Informatics (version 3.84).

BD Synapsys Informatics is an optional integrated informatics solution available to customers using the BD Veritor Plus System, a portable instrument delivering SARS-CoV-2 antigen test results in approximately 15 minutes, and the BD MAX System, a molecular diagnostic platform returning results in two to three hours. Both systems have been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to perform SARS-CoV-2 diagnostic testing.

The BD Synapsys solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor and/or BD MAX systems. The solution also offers configured reporting capabilities, which allow customers in the U.S. to generate reports in accordance with the U.S. Coronavirus Aid, Relief, and Economic Security (CARES) Act. The CARES Act requires COVID-19 testing facilities to report testing data to local and federal health authorities daily, including the number of tests performed, results and key patient demographics. Additional configured reports can be developed, as needed.

"BD Synapsys Informatics unifies instrument-read COVID-19 test results from the BD Veritor and BD MAX systems," said Rajeev Sehgal, director of Informatics for BD Integrated Diagnostics Solutions. "The solution's new encrypted reporting capabilities reduce the burden associated with manual reporting. This empowers customers to focus on what matters most: Caring for their patients."

Used with the BD Veritor Plus System and/or the BD Max System, the BD Synapsys Informatics 3.84 solution allows customers to export all SARS-CoV-2 test results in a single daily report.

"Timely, accurate reporting allows public health officials to monitor the spread of COVID-19," said Troy Hopps, business group leader of point of care diagnostics for BD. "For COVID-19 testing facilities – including labs, hospitals and nursing homes – the BD Synapsys™ Informatics solution's new reporting capabilities, supported by secure connectivity, simplifies the process of reporting test results to public health authorities."

BD has the release.

More COVID-19 coverage HERE.